Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



Peanut Allergies: A Hard Nut to Crack


 

New Guidelines, Potential Therapy Offer a Shift in the Prevailing Wind

Peanuts are considered one of nature's healthiest foods ... unless, of course, you are one of the three million Americans allergic to peanuts and tree nuts. For those with severe allergy, even minimal exposure to peanut protein could prove deadly.

Updated Guidelines

While it might seem counterintuitive to parents fearful of harming their children, the potential severity of an allergic reaction is one of the reasons ... backed by science ... that clinical guidelines were changed in January to call for a much earlier introduction of peanuts in the diet. For years, healthcare providers have told new parents not to introduce peanut products until the age of two. Yet, the incidence rate of peanut allergies has continued to climb in the United States.

In January, the National Institute of Allergy and Infectious Disease (NIAID), along with the American Academy of Allergy, Asthma & Immunology (AAAAI) plus 24 other organizations, recommended children at high risk of peanut allergy be introduced to peanuts at four to six months instead of avoiding all peanut-containing foods.

The about-face was prompted by findings from the NIAID-funded Learning Early About Peanut (LEAP) allergy trial, which showed children at high risk of developing a peanut allergy were far less likely to do so (an 81 percent relative reduction) when introduced to peanuts before turning a year old. After the LEAP results came out, the NIAID convened a panel of experts for a review of literature and other studies that culminated in the addendum updating the 2010 Guidelines for the Diagnosis and Management of Food Allergy in the United States. The new addendum, which was published in the Jan. 5 edition of the AAAAI's Journal of Allergy and Clinical Immunology, has detailed information on when and how to introduce peanuts to infants at three different risk levels. The new guidelines also call for adults to consult a healthcare provider before introducing peanuts to a child's diet.

Infants at highest risk of peanut allergy - those with severe eczema, egg allergy or both - should be brought to a specialist for peanut sIgE or skin prick testing to assess signs of allergy and to decide the safest way to introduce the peanut, which could include supervised feeding under the watchful eye of a healthcare provider. In the LEAP study, only 1.9 percent of infants at high risk of allergy who were introduced to peanuts early went on to develop a peanut allergy by age five, as compared to 13.7 percent of children in the same risk group who avoided peanuts.

To access the addendum guidelines, go online to the 'Diseases and Conditions' section of NIAID.NIH.gov.

Peanut Patch

For those who have already developed a peanut allergy, a new form of epicutaneous immunotherapy has continued to show promise in clinical trials. The Viaskin® Peanut patch has progressed from a Phase Ib safety trial launched in July 2010 to two Phase III trials now underway focused on safety, long-term efficacy and real world use.


Viaskin Peanut patch (Photo: Courtesy DBV Technologies)

Luis Salmun, MD, senior vice president of Global Medical Affairs for clinical-stage biopharma company DBV Technologies, said the company's novel patch mechanism is very exciting and could be used with other allergens and diseases, as well. In addition to the peanut patch, DBV Technologies is exploring the platform to address milk and egg allergies and is in a Phase I trial for pertussis.

"This is a new platform for technology that uses the skin as an immune organ ... not just a barrier but actually as an immune organ," said Salmun.

The Viaskin technology differs from other patches presently on the market, such as those to wean individuals from smoking, "The kind of patches that are used currently are absorbed quickly through the skin," Salmun explained. "With the Viaskin patch, what's different is that there is a space between the patch and the skin. This membrane is electrostatically charged with peanut protein. The space allows for the very slow release of the peanut protein from the patch to the skin."

He continued, "Once deposited on the skin, it (peanut protein) binds to Langerhans cells, the antigen-presenting cells, and goes directly to the lymph nodes, bypassing the bloodstream." Salmun pointed out this route, which was studied in animal models, minimizes the chance of systemic reaction and anaphylaxis. "That is one of the key advantages of this technology."

Thus far found to be most efficacious in the pediatric population, Salmun said the dose released in children aged four-11 is 250 micrograms - approximately 1/1000th of a peanut in each patch. "What is so exciting is that such a negligible amount of peanut protein can lead to such an immune response," noted Salmun.

At the recent AAAAI annual meeting, a team from DBV presented findings from a two-year extension of their successful yearlong, double blind, placebo-controlled, randomized trail for Viaskin Peanut. In the two-year extension arm, participants were treated with a daily 250 µg peanut patch. At the end of the third year, 83.3 percent of children aged six-11 showed response to treatment, as compared to 53.6 percent at the end of the one-year trial. In this trial, a responder after three years of treatment was defined as a patient who reached an eliciting dose equal to or greater than 1,000 milligrams of peanut protein, or had a greater than 10-fold increase of the eliciting dose compared to the patient's baseline eliciting dose at the beginning of the Phase II trial.

Similarly, children using the Viaskin Peanut patch saw a marked increase in the amount of peanut they could ingest during food challenges. At study entry, the median cumulative reactive dose was 44 milligrams of peanut protein. For those who completed three years in the extended trial, the median cumulative reactive dose rose to 1,440 milligrams.

Salmun pointed out, "The goal of Viaskin is to decrease the chances of a reaction to an accidental exposure ... not to eat PBJ sandwiches." However, he continued, it's an important goal given the number of Americans with peanut allergies and the difficulty in predicting the severity of reaction on any given day, which might range from a skin reaction to severe anaphylaxis. "The incidence of peanut allergy has increased significantly over the past decade," he added.

While the latest studies have shown increased tolerance by extending use of the patch from one year to three, Salmun said there isn't an exact answer at this point as to the optimal timeframe for wearing the disposable patch. "How to stop ... when to stop ... we don't have an exact answer at this time," he noted. In fact, Salmun continued, "I don't think there's going to be a black or white answer ... it will have to be evaluated by the physician."

Results from the latest Phase III studies are expected in the second half of 2017. What is already known is that patients have been able to tolerate the patch very well with no serious adverse events being reported. The trials have also enjoyed well over 95 percent compliance rate for the small, easily applied patch. Salmun said there are no constraints or restrictions with the patch and that children in the trials have been able to swim, run and play sports as normal.

In a Nutshell

Quick facts and stats about food allergies according to FARE (Food Allergy Research & Education):

  • Researchers estimate that up to 15 million Americans have food allergies.
  • Potentially deadly, food allergies affect 1 in every 13 children in the United States, which equals about two children in every classroom.
  • Food allergies are on the rise. According to a study released in 2013 by the Centers for Disease Control and Prevention, food allergies among children increased approximately 50 percent from 1997 to 2011.
  • The CDC reported food allergies result in more than 300,000 ambulatory care visits a year for children under age 18.
  • Food allergy reactions account for more than 200,000 emergency department visits each year ... about one every three minutes.
  • Food allergy is the leading cause of anaphylaxis outside the hospital setting, and teenagers and young adults with food allergies are at the highest risk of fatal food-induced anaphylaxis.
  • Children with food allergies are 2-4 times more likely to have other related conditions like asthma and other allergies.
  • Having a parent who suffers from any type of allergic disease - from hay fever or eczema to asthma or food allergies - increases a child's risk for food allergies.
  • Food allergies can begin at any age and cross all races and ethnicities.
  • Eight foods account for the majority of all reactions: milk, eggs, peanuts, tree nuts, soy, wheat, fish and shellfish.
  • For more information, go online to foodallergy.org.

WEB:
Peanut Allergy Addendum Guidelines: NIAID
Peanut Allergy Addendum Guidelines Article in JACI
DBV Technologies
Viaskin® Peanut

 
Share:

Related Articles:


Recent Articles

Post-Flu Risks A Growing Concern For The Elderly

Infectious disease experts are warning that flu can lead to an increased risk of heart attack, stroke and disability in elderly patients for months after they have recovered from their illness.

Read More

Meharry & HCA Join Forces for Training Physicians

Meharry students to train in HCA system.

Read More

Hospital Groups File Lawsuit To Stop Significant Payment Cuts For 340B Hospitals

Today, the American Hospital Association (AHA), the Association of American Medical Colleges (AAMC) and America's Essential Hospitals filed a lawsuit against the U.S. Department of Health and Human Services (HHS) in the U.S. District Court for the District of Columbia to prevent significant Medicare payment cuts for hospitals that participate in the 340B Drug Pricing Program.

Read More

CMS proposes policies to lower the cost of prescription drugs and combat the opioid crisis

The proposed rule eliminates administrative hurdles to providing more affordable prescription drugs and will allow Medicare to combat opioid overprescribing and abuse.

Read More

Tax Reform & Healthcare

Medicare cuts and repeal of the individual mandate are two areas of tax reform directly impacting healthcare.

Read More

Senate HELP Committee Hearing on Gene Editing Technology

On Nov. 14, the Senate health committee held a hearing on the gene editing method CRISPR to learn more about the technology from expert witnesses, which included Dr. Matthew Porteus, associate professor of Pediatrics at Stanford University; Katrine Bosley, CEO and president of Editas Medicine; and Dr. Jeffrey Kahn, director of the Johns Hopkins Berman Institute of Bioethics at Johns Hopkins School of Public Health.

Read More

Nashville Health Care Council Hosts Panel Discussion on Pharma/Provider Collaborations in Health Care

On Nov. 13, the Nashville Health Care Council hosted a panel discussion on collaborations between the pharmaceutical and healthcare provider sectors and how those collaborations can drive change in healthcare.

Read More

Tennessee Health Care Hall of Fame Class of 2017

Six healthcare luminaries were recently inducted into the Tennessee Health Care Hall of Fame.

Read More

NMGMA 10 Minute Takeaway

Nashville Medical News recently had the opportunity to chat with new NMGMA president Joy Testa.

Read More

Tennessee Joins Medical Licensing Compact

A new Tennessee law will make it easier for area physicians to practice across state lines beginning in 2019 as part of the Interstate Medical Licensure Compact.

Read More

Email Print
 
 

 

 


Tags:
AAAAI, American Academy of Allergy, Anaphylaxis, Asthma & Immunology, Clinical Guidelines, DBV Technologies, Food Allergy, LEAP Study, Luis Salmun, National Institute of Allergy and Infectious Disease, NIAID, Peanut Allergy, Peanut Patch, Viaskin Peanut
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: